R&F Capital Advisors’s Altimmune ALT Stock Holding History

R&F Capital Advisors’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-76	Closed	-$74K	–	670
2016 Q4	$74K	Buy	+76	New	+$68.1K	0.03%	460

Other funds holding ALT

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

R&F Capital Advisors's ALT Position: Q1 2017 in Review

R&F Capital Advisors sold out of Altimmune (ALT) in Q1 2017, closing a stake of 76 shares — an estimated $74K sold.

R&F Capital Advisors first reported a position in ALT in Q4 2016 and held it in 1 quarter. The position peaked at $74K in Q4 2016. 71 funds tracked by Wall St. Rank hold ALT as of Q1 2017.

R&F Capital Advisors reported no remaining Altimmune position as of Q1 2017 after selling out during the quarter.
R&F Capital Advisors sold 76 Altimmune shares in Q1 2017, an estimated $74K.
R&F Capital Advisors first reported a position in Altimmune in Q4 2016 and held it in 1 quarter.
R&F Capital Advisors's Altimmune position peaked at $74K in Q4 2016.
71 funds tracked by Wall St. Rank held Altimmune as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.